Drug Profile
Research programme: gene editing therapeutics - bluebird bio
Latest Information Update: 31 Oct 2022
Price :
$50
*
At a glance
- Originator bluebird bio
- Class Endodeoxyribonucleases
- Mechanism of Action Gene modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Unspecified
Most Recent Events
- 31 Oct 2022 Preclinical development is ongoing in USA (bluebird bio pipeline, October 2022)
- 28 Mar 2019 No recent reports of development identified for preclinical development in Unspecified in USA
- 02 Feb 2015 Preclinical trials in Undefined indication in USA (unspecified route)